source
- Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partnersHengrui Pharmaceuticals has become a leading source of innovative drugs in China, outpacing many peers in the current licensing boom. In May the company signed a $15.2 billion licensing pact with…
- Lilly-backed TRex Bio raises $117M in IPO as hypertension biotech Retension secures $45M listingTRex Bio, a biotech backed by Eli Lilly, completed its initial public offering, generating $116.7 million in gross proceeds. The company sold 8.3 million shares at $14 each, landing at the lower en…